Pharma marketing works within the Drugs and Magic Remedies Act, which restricts direct-to-consumer advertising of many drug categories, focusing instead on B2B channels to healthcare professionals and distributors, or general health-education content where DTC is permitted. Measured against qualified distributor or HCP inquiries.
What matters most for pharma?
- Compliance with Drugs and Magic Remedies Act restrictions on DTC advertising
- B2B content targeting HCPs and distributors specifically
- Health-education content where direct-to-consumer messaging is permitted
Which channels work for pharma?
| Channel | Role |
|---|---|
| Lead Generation | B2B distributor and HCP inquiry generation |
| Content Marketing | Compliant health-education content |
| SEO | Product and molecule-information pages for B2B research |
Most of the world does not allow direct advertising of prescription drugs
New Zealand and the United States are the only high-income countries that allow unrestricted direct-to-consumer advertising of branded prescription medicines (The Conversation). In India, the Drugs and Magic Remedies (Objectionable Advertisements) Act restricts advertising claims for treating a long list of conditions, and pharma promotion to doctors is covered by the Uniform Code for Pharmaceutical Marketing Practices. In the UK, prescription-only medicines cannot be advertised to the public (ASA and CAP enforcement notice). So pharma digital marketing is mostly about healthcare professionals, distributors, institutions and export buyers.
What works within the rules
- HCP content: clinical evidence summaries, dosing information and educational resources behind appropriate access controls
- Disease awareness: unbranded patient education where permitted, reviewed by medical and regulatory teams
- Distributor and export funnels: product portfolio pages, certifications, regulatory approvals and RFQ forms
- Corporate reputation: manufacturing quality, research and talent content on LinkedIn
- Search: molecule, formulation and generic name searches from buyers and pharmacists
Export opportunity in 2026
The India and UK trade agreement, in force from 15 July 2026, cuts UK tariffs on chemicals and pharmaceuticals by up to 8% for Indian exporters (PIB, Government of India). Regulatory approval still governs market entry, but buyers researching new suppliers start with a search and a website. Clear portfolio, quality and regulatory pages are the entry ticket.
Every piece of pharma content needs medical and regulatory review before publication. We build the review step into the timeline so it does not become a bottleneck.
How we measure it
Qualified HCP engagement, distributor and export RFQs, sample requests and tender invitations, not consumer sales. For wider B2B export marketing, see manufacturing and export marketing.